gms | German Medical Science

45. Kongress der Deutschen Gesellschaft für Rheumatologie, 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

06.09. - 09.09.2017, Stuttgart

Article

Send article

Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis

Meeting Abstract

Search Medline for

  • Alice B. Gottlieb - Department of Dermatology, New York Medical College, Metropolitan Hospital New York, New York, USA
  • Elaine Husini - Cleveland Clinic, Cleveland, USA
  • Catherine Shuler - Eli Lilly and Company, Indianapolis, USA
  • Russel Burge - Eli Lilly and Company, Indianapolis, USA
  • Chen-Yen Lin - Eli Lilly and Company, Indianapolis, USA
  • Chin Lee - Eli Lilly and Company, Indianapolis, USA
  • Dafna Gladman - Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada
  • Kerstin Engel - Lilly Deutschland GmbH, Bad Homburg

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Stuttgart, 06.-09.09.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocRA.40

doi: 10.3205/17dgrh183, urn:nbn:de:0183-17dgrh1833

Published: September 4, 2017

© 2017 Gottlieb et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Background: Results from the phase 3 trial, SPIRIT-P1, showed that ixekizumab significantly improved patient reported outcome (PRO) measures at week 24 (Wk24).

Methods: We evaluated the effect of ixekizumab on PROs at Wk52. Patients with active psoriatic arthritis (N=417) were randomized to ixekizumab 80mg every 4 (IXEQ4W) or 2 (IXEQ2W) weeks (after 160mg starting dose); adalimumab 40mg; or placebo, in the double-blind treatment period (Wk0–24). 381 patients entered the extension period (Wk24–52). Placebo- and adalimumab treated patients were randomly re-assigned to IXEQ4W or IXEQ2W at Wk16 (inadequate responders) or Wk24; adalimumab-treated patients started ixekizumab at Wk24 (inadequate responders) or Wk32, after 8-wk wash-out. Physical function and quality-of-life were impaired at baseline.

Results: 69% of patients treated with ixekizumab achieved ACR20 response at Wk52. In these patients, improvements in presenteeism, work productivity and activity impairment at Wk52 were consistent with those seen at Wk24, and the percentage achieving minimally clinically important difference from baseline HAQ DI score (≥0.35) was sustained at Wk52.

Conclusion: Patients receiving adalimumab→ixekizumab showed improvements in ACR20 response and most PRO measures, consistent with those treated with ixekizumab for up to Wk52. Ixekizumab provided improvements in physical function, quality-of-life, and work productivity through 52 weeks.